Get the Stockscreener App
2.69
3.07%
0.08
After Hours:
2.71
0.02
+0.74%
Relay Therapeutics Inc stock is traded at $2.69, with a volume of 1.63M.
It is up +3.07% in the last 24 hours and down -23.36% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$2.61
Open:
$2.56
24h Volume:
1.63M
Relative Volume:
0.69
Market Cap:
$435.67M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-0.9607
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+21.17%
1M Performance:
-23.36%
6M Performance:
-59.49%
1Y Performance:
-56.68%
1-Day Range:
$2.54
$2.70
1-Week Range:
$2.17
$2.81
52-Week Range:
$1.775
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
2.69 | 435.67M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Franklin Resources Inc. Sells 1,338,037 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Wells Fargo & Company Begins Coverage on Relay Therapeutics (NASDAQ:RLAY) - Defense World
Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation - Nasdaq
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Relay Therapeutics at Equalweight With $4 Price Target - marketscreener.com
Relay Therapeutics (RLAY) Assigned Equal Weight by Wells Fargo | RLAY Stock News - GuruFocus
Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace
Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance
Relay Therapeutics: Trying To Find That Right Price - Seeking Alpha
Corebridge Financial Inc. Acquires 7,314 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Vanguard Group Inc. Acquires 566,595 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics Inc (NASDAQ: RLAY): Blank Check On Growth? - stocksregister.com
KLP Kapitalforvaltning AS Purchases New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
American Century Companies Inc. Buys 51,499 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Norges Bank Takes $23.82 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Raymond James Financial Inc. Invests $779,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Cancer drug developer cuts staff for the third time in a year - The Business Journals
Relay Therapeutics Inc (RLAY) Recovers -2.97% From Low: Are We There Yet? - stocksregister.com
Thrivent Financial for Lutherans Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Teacher Retirement System of Texas Purchases 5,492 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics stock hits 52-week low at $2.44 - Investing.com India
Relay Therapeutics stock hits 52-week low at $2.44 By Investing.com - Investing.com UK
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Virtu Financial LLC - Defense World
Relay Therapeutics’ SWOT analysis: promising drug data boosts stock outlook - Investing.com Australia
Relay Therapeutics’ SWOT analysis: promising drug data boosts stock outlook By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! - Insider Monkey
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by HighTower Advisors LLC - Defense World
Charles Schwab Investment Management Inc. Decreases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges - Investing.com India
Bank of New York Mellon Corp Buys 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Investor Alert: What’s Really Going On At Relay Therapeutics Inc (NASDAQ: RLAY) - Stocks Register
Victory Capital Management Inc. Has $63,000 Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Steward Partners Investment Advisory LLC Purchases 4,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Head-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition - Investing.com India
Arizona State Retirement System Acquires 7,547 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):